They identified a novel epitranscriptomic mechanism where YTHDC1 regulates the PTEN/PI3K/AKT signalling pathway in an m6A‐dependent manner, affecting chemotherapeutic outcomes in bladder cancer.222. Here, YTHDC1 is linked to urinary bladder cancer.